Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Sugammadex vs Neostigmine for Reversal of Neuromuscular Blockade
NCT05718934Phase 4Completed
- Start
- Nov 2022
- Primary completion
- Dec 2023
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Sugammadex in neuromuscular blockade (NMB) (2 arms). Primary endpoint: Time for recovery from moderate neuromuscular blockade. Started Nov 2022; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT05718934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718934.